
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
PHILADELPHIA, April 17, 2025 (GLOBE NEWSWIRE) --
BioAge Labs, Inc. (NASDAQ: BIOA)
If you have held BioAge Labs, Inc. (NASDAQ: BIOA) shares continuously since on or shortly after its September 26, 2024 IPO, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/bioage-shareholder-investigation/, contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more.
Why? BioAge completed its initial public offering on September 27, 2024, selling 12.65 million shares at $18 per share. However, less than three months later, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. In response to the news, BioAge's stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.
Following this news, a federal securities fraud class action complaint was filed in which it is alleged that BioAge and ten of its Officers and Directors made materially false and/or misleading statements in its initial public offering concerning its STRIDES Phase 2 clinical trial and that these investors sustained damages as a result thereof.
Specifically, it is alleged that BioAge's final prospectus for its IPO represented the significance and benefits of azelaprag for the treatment of obesity in older adults. Defendants touted BioAge's lead product candidate azelaprag in connection with the Company's ongoing STRIDES with expectations of topline results in 2025. Defendants also mentioned its collaboration with Lilly's Chorus clinical development organization who would be advising and assisting on all aspects of the STRIDES trial design and execution. Defendants further discussed the potential for a second Phase 2 clinical trial combining azelaprag and semaglutide to treat obesity in individuals ages 18 years and older. Therefore, the initial public offering represented to the public that there were no safety concerns and the Company expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial. Contrary to these representations, BioAge discontinued the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after several subjects showed elevated levels of liver enzymes warning of potential organ damage. As a result, Defendants discontinued the clinical trial and halted further enrollment. Given the fact that Defendants failure to disclose the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies, Defendants' statements in BioAge's registration statement were allegedly false and/or materially misleading at the time of the initial public offering.
What You Can Do Now? Current BioAge shareholders who have held BioAge shares since on or shortly after its September 26, 2024 IPO, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/bioage-shareholder-investigation/, contact us at [email protected], or call 267-507-6085. #BioAge $BIOA
NAPCO Security Technologies, Inc. (NASDAQ: NSSC) Class Action Survives Motion to Dismiss
If you are a Current NAPCO (NASDAQ: NSSC) shareholder who has held NAPCO shares since prior to November 7, 2022, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Click here to join or learn more: https://grabarlaw.com/the-latest/Napco-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085.
Why? Key allegations in a recently filed securities fraud class action complaint have survived a motion to dismiss. That complaint alleges that NAPCO Security Technologies, Inc. (NASDAQ: NSSC), through certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that: (1) NAPCO failed to address any material weaknesses with internal controls regarding cost of goods sold ('COGS') and inventory; (2) NAPCO downplayed the severity of material weaknesses regarding their internal controls; (3) NAPCO's unaudited financial statements from September 30, 2022 to the present included 'certain errors' such as overstating inventory and understanding net COGS, resulting in overstated gross profit, operating income and net income for each period; (4) as a result, NAPCO would need to restate its previously filed unaudited financial statements for certain periods; and (5) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
On April 11, 2025, the federal court determined that key allegations would survive Defendants' motion to dismiss the complaint.
In so doing, the Court stated: 'Plaintiffs have adequately stated Exchange Act claims by pleading scienter [knowledge of wrongdoing] through defendants' unusual stock sales and by plausibly alleging loss causation between the corrective announcement and stock price drop. Plaintiffs have also stated Securities Act claims against NAPCO and the underwriter defendants.'
'Taking the well-pleaded facts as true, there is no question that plaintiffs have adequately pled scienter. First, the stock sales were highly unusual in timing and amount. As to amount, the total proceeds of over $108 million from stock sales by the officer defendants weigh in favor of a motive. . . . And the officer defendants sold hefty percentages of their holdings – 48.5% for Soloway and 45.5% for Buchel.'
What To Do Now: If you have held NAPCO shares since prior to November 7, 2022, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. If you would like to learn more about this matter, please visit https://grabarlaw.com/the-latest/Napco-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085.
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
If you have held Treace Medical Concepts (NASDAQ: TMCI) shares continuously since prior to May 8, 2023, you can seek corporate reforms, the return of funds back to the Company, and a court approved incentive award at no cost you. Visit https://grabarlaw.com/the-latest/treace-shareholder-investigation/, or contact Joshua H. Grabar at [email protected] or call 267-507-6085 to learn more.
Why? A recently filed securities class action complaint alleges that, Treace Medical Concepts, Inc. (NASDAQ: TMCI), via certain of its officers, made materially false and/or misleading statements and failed to disclose adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, Treace Medical's revenue declined, and the Company needed to accelerate its plans to offer a product that served as an alternative to osteotomy (a surgical procedure involving the cutting and realignment of a bone to improve its position or function); and (3) Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What You Can Do Now: Current Treace shareholders who have held Treace shares since prior to May 8, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/treace-shareholder-investigation/, contact us at [email protected], or call 267-507-6085. #Treace $TMCI
Virtu Financial Inc. (NASDAQ: VIRT) Class Action Survives Motion to Dismiss:
A federal securities fraud class action complaint alleging that Virtu Financial Inc. (NASDAQ: VIRT), and certain of its officers failed to disclose to investors that it had improper safeguards in place for sensitive trader information, has survived a motion to dismiss.
Virtu shareholders who have continuously held Virtu shares since prior to November 7, 2018, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more or join by clicking https://grabarlaw.com/the-latest/Virtu-shareholder-investigation/, contact Joshua H. Grabar at [email protected], or call 267-507-6085.
WHY: A securities fraud class action complaint alleges that Virtu Financial (NASDAQ: VIRT), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) the Company maintained deficient policies and procedures with respect to its information access barriers; (ii) accordingly, Virtu had overstated the Company's operational and technological efficacy as well as its capacity to block the exchange of confidential information between departments or individuals within the Company; (iii) the foregoing deficiencies increased the likelihood that the Company would be subject to enhanced regulatory scrutiny; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
On March 17, 2025, a federal Court determined that key allegations were sufficiently pled to survive defendants' motion to dismiss.
According to the Court's Order, 'essentially anyone at Virtu, including its proprietary traders' could directly access this material non-public information from at least January 2018 through April 2019, and to do so, Virtu traders only needed to use a 'widely known and frequently shared username and password.'
WHAT YOU SHOULD DO NOW: If you are a current Virtu shareholder who has held Virtu stock since on or before November 7, 2018, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever.
If you would like to learn more about this matter, you are encouraged visit https://grabarlaw.com/the-latest/Virtu-shareholder-investigation/, contact Joshua H. Grabar at [email protected] or call 267-507-6085. $VIRT #VirtuFinancial
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Fortrea Names Anshul Thakral Chief Executive Officer
Thakral succeeds Interim CEO, Peter M. Neupert, who will remain chairman of the board DURHAM, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the 'Company'), a leading global contract research organization (CRO), today announced that Fortrea's Board of Directors (the 'Board') named Anshul Thakral as Fortrea's CEO, effective August 4, 2025. He was also appointed to serve as a director on the Company's Board, effective as of that date. Thakral succeeds Interim CEO, Peter M. Neupert, who will remain as chairman of the board. Thakral brings more than 20 years of experience in life sciences as an executive and commercial leader, advisor and entrepreneur. He will focus on executing the Company's transformation plan and sharpening Fortrea's focus on profitable growth. Further, he will oversee additional value creation efforts for customers, employees and shareholders. 'Anshul is an exceptional leader with extensive life sciences experience, deep familiarity with the CRO industry, a commitment to innovation and a proven record of building companies and growing revenue,' said Neupert. 'His strong business development capabilities, commercial insights and relentless focus on customer engagement make him ideally suited to lead Fortrea. Further, he also shares the Company's commitment to modernizing the clinical trials process and combining the best talent, science and technology to effectively and efficiently respond to changing customer and patient needs. We are delighted to welcome Anshul to Fortrea as we seek to capitalize on the significant growth opportunities we see ahead and meet our customers' needs.' 'Since its founding, the Fortrea team has earned a strong reputation for leading with science and creating a differentiated customer experience,' said Thakral. 'I share the team's passion for customers and the patients they serve, and I'm honored to take the reins at this pivotal moment. It is an exciting opportunity to lead the organization as it continues to deliver flexible and agile drug development solutions that accelerate the delivery of life-changing treatments to patients. I'm confident this company can execute on its patient and customer-focused mission while delivering profitable growth, which ultimately delivers value for shareholders.' About Anshul Thakral Thakral joins Fortrea from Launch Therapeutics, a company he co-founded at which he served as CEO. Previously, he held several executive leadership roles at PPD, a leading CRO, including chief commercial officer and executive vice president of Peri- and Post-Approval Services. He led PPD Biotech, which contributed to PPD's growth. Prior to PPD, Thakral ran the global life sciences business unit at Gerson Lehrman Group and served as an Associate Principal at McKinsey & Company in the healthcare practice. He currently serves on the board of directors of TriNetX, Saama Technologies and Orsini Specialty Pharmacy. He earned his B.S. and M.S.E. in Biomedical Engineering from Johns Hopkins University and his MBA from the Wharton School at the University of Pennsylvania. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at and follow us on LinkedIn and X (formerly Twitter). Cautionary Statement Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, the Company's growth opportunities. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as 'guidance,' 'expect,' 'assume,' 'anticipate,' 'intend,' 'plan,' 'forecast,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from the Company's expectations due to a number of factors, including, but not limited to, the following: the Company's ability to successfully implement its business strategies and execute its long-term value creation strategy; risks and expenses associated with the Company's international operations, tariff policies, trade sanctions and other trade restrictions and currency fluctuations; the Company's customer or therapeutic area concentrations; any further deterioration in the macroeconomic environment or further changes in government regulations and funding, which could lead to defaults or cancellations by the Company's customers; the risk that the Company's backlog and net new business may not be indicative of the Company's future revenues and that the Company might not realize all of the anticipated future revenue reflected in the Company's backlog; the Company's ability to generate sufficient net new business awards, or the possibility that net new business awards are delayed, terminated, reduced in scope, or fail to go to contract; if the Company underprices its contracts, overruns its cost estimates, or fails to receive approval for, or experiences delays in documentation of change orders; and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the 'Risk Factors' Section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this release and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Contacts: Hima Inguva (Investors) – 877-495-0816, Sue Zaranek (Media) – 919-943-5422, media@ Kate Dillon (Media) – 646-818-9115, kdillon@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
$16.5M Storm Water Revenue Bond secured by the city of Norfolk
NORFOLK, Va. (WAVY) – The City of Norfolk issued a $16.5 million Storm Water Revenue Bond through the Virginia Clean Water Revolving Loan Fund on May 29, which is designed to fund storm water infrastructure improvements across Norfolk. The various projects include enhancements to St. Paul's Blue-Greenway and restoration of shorelines and wetlands across the city. The total cost of the project is expected to reach nearly $18.5 million, but the city is receiving nearly $2 million in principal forgiveness. This means the remaining balance will come at no extra cost to Norfolk. For more information on the project visit the link . Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
22 minutes ago
- Yahoo
‘Third-best season ever': Over 6.5 million skiers visited Utah's resorts during the season
SALT LAKE CITY () — 'Greatest snow on Earth,' Utah's long-running slogan, is proving itself true after another successful season at Utah's ski resorts. According to Ski Utah, this last season was the third-best in state history. There are 15 ski resorts across Utah, and together they recorded 6,503,635 visitors during the 2024-25 season, which has just wrapped up. According to a press release from Ski Utah, this is the third-highest number of skier visits in state history. This season's skier visits were down 3.6% from last year, the press release says, but the more than 6.5 million visitors this year show a 3.3% increase over Utah's five-year average. Utah's economy benefits greatly from recreation at the ski resorts. Ski Utah's president and CEO, Nathan Rafferty, emphasized skiing's impact on Utah. EXCLUSIVE: Utah man who underwent 120 surgeries advocates for rare disease awareness in Washington, D.C. 'To hit our third-best season ever and generate $2.51 billion for Utah's economy is a major win,' Rafferty is quoted in the release. 'The ski industry in Utah supports approximately 25,000 jobs, and with the 2034 Olympic and Paralympic Winter Games on the horizon, the eyes of the world will be on us once again. We're excited about the opportunities ahead and grateful to all who helped make this season a success.' Ski Utah says that ski resorts are already hard at work to prepare for the upcoming 2034 Winter Olympics. In the next two years alone, 13 new lifts are expected to finish construction and open, and many resorts are planning upgrades to their mountain areas. 'Utah's future as a global winter destination remains as promising as ever,' Ski Utah concluded. Arizona man drowns along San Juan River in Glen Canyon National Recreation Area Charges for trespassing on border military zones 'not going away' Former Utah Supreme Court Chief Justice Gordon Hall dies at 98 Two women charged with felonies after late-night assault in Logan, charges say Death penalty expert weighs in on Menzies competency ruling and appeal Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.